Article Text
Statistics from Altmetric.com
On 1 September 2015, the UK became the world’s first country to introduce a novel meningococcal B vaccine (Bexsero) into its national childhood immunisation programme. Bexsero is the only market authorised meningococcal B vaccine in the UK. Meningococcal B strains accounts for ~80% of all laboratory confirmed cases of invasive meningococcal disease (IMD) in England and Wales1. Bexsero is estimated to protect against 73%–88% of the meningococcal B strains causing invasive disease in England and Wales2
After observing more instances of clinical instability in our immunised neonates following the introduction of the new …
Footnotes
Original reference: None
Handling editor Martin Ward Platt
Contributors AM conceived the project. SS and DM were responsible for the data collection. Statistical input by AR.
Competing interests None declared.
Provenance and peer review Not commissioned; internally peer reviewed.